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i. Summary/Abstract  
Fluorescence polarization (FP) can be used to measure binding of a small fluorescent ligand 
to a larger protein because the ligand rotates more rapidly in its free form than when bound. 
When excited with plane polarized light, the free fluorescent ligand emits depolarized light, 
which can be quantified. Upon binding, its rotation is reduced and more of the emitted light 
remains polarized. This allows FP to be used as a non-destructive assay of ligand binding. 
Here we describe a fast, high-throughput FP assay to quantify the binding of fluorescently 
labelled inositol 1,4,5-trisphosphate (IP3) to N-terminal fragments of the IP3 receptor. The 
assay is fast (1-6 hours), it avoids use of radioactive materials and when measurements are 
performed at different temperatures, it can resolve Gibbs free energy (ΔG°), enthalpy (ΔH°) 
and entropy (ΔS°) changes of ligand binding.  
 
ii. Key Words  
IP3 receptor, fluorescence polarization, ligand binding, affinity, thermodynamics.  
 
1. Introduction 
Molecular interactions underpin all biological activity. Quantitative analysis of ligand-protein 
interactions is essential to understanding cellular behaviour. Although several methods have 
been applied for quantitative analysis of ligand-protein interactions [1], most studies have 
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used radioligand binding assays. These methods are laborious and time-consuming, they 
are not amenable to high-throughput analyses, and they use expensive and environmentally 
unfriendly radioactive materials. A major drawback of radioligand binding assays is the need 
to separate bound from free ligand, which hampers quantification of low-affinity interactions. 
Fluorescence polarization (FP) assays provide an alternative approach that avoids these 
problems. FP measures the change in rotational speed of a fluorescent ligand during its 
excited lifetime as a consequence of it binding to a larger protein or receptor. A fluorophore 
is optimally excited (typically in 10-15s) by plane-polarized light in a preferred orientation and 
then (usually) [2, 3] emits light in the same orientation. If there is no movement of the 
molecule during the fluorescent lifetime of the fluorophore (typically ns), then 60% of all 
emitted light would be detected in the same plane as the exciting light (parallel) and 20% in 
each of the other two planes (perpendicular) (Fig. 1A). But if the molecule rotates (<ns 
timescales for small molecules), it will no longer be aligned and when the fluorophore emits 
its light <60% will be aligned with the source (Fig. 1A). When plane-polarized light is used for 
excitation, then the intensities of the light detected in the perpendicular (I) and parallel 
planes (I) with respect to the excitation source are related to the polarization (P) and 






The denominator in equation 2 is the total light (2I to take account of both perpendicular 
planes); A therefore provides the most algebraically convenient description of FP because 
anisotropy components can be summed (polarization values cannot) [4]. A fluorescent 
molecule with the properties described above would then (with no rotation) have: 
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If the molecule tumbles so that it becomes randomly re-oriented during the fluorescent 
lifetime, then both A and P become 0 (because I = I). With other conditions (viscosity, etc) 
constant, size determines whether the molecule can re-orient during the fluorescent lifetime 
[2, 3]. For large molecules, the speed of tumbling is slower than typical fluorescent lifetimes; 
now a molecule is likely to retain the same orientation throughout the interval between 
absorbing and emitting a photon. Binding of a fluorescent ligand (D*) to a larger protein (R) 
increases the effective size of the fluorescent complex and it therefore tumbles more slowly, 
causing more emitted light to remain polarized with respect to the excitation light (Fig. 1B). 
This allows FP to be used as a non-perturbing assay of ligand binding (Fig. 1A-C). 
[Fig 1 near here] 
Inositol 1,4,5-trisphosphate receptors (IP3R) are intracellular channels, which are expressed 
in the endoplasmic reticulum of almost, if not all cells [5]. They mediate the initial release of 
Ca2+ from intracellular stores evoked by cell-surface receptors that induce IP3 formation and 
contribute to regulating a myriad of cellular processes [5].  The functional channel is a 
tetramer of the same or different subunits encoded by three different IP3R genes (IP3R1-3) 
and its opening requires binding of both IP3 and Ca
2+ [6]. The IP3-binding core (IBC, residues 
224-604 of IP3R; Fig. 2A) of each subunit is entirely responsible for binding IP3 [7]. Residues 
immediately preceding the IBC (residues 1-223, suppressor domain; SD) decrease the IP3-
binding affinity. Thus, the IBC displays substantially higher affinity for IP3 than the full-length 
IP3R or an N-terminal fragment comprising the SD and IBC (residues 1-604; N-terminal; NT) 
[8] (Fig. 2A). IP3 binding initiates channel activation by closing the clam-like IBC and 
displacing the SD [9, 10], which is essential for channel gating [8, 11]. These conformational 
changes are probably transmitted directly to the channel pore via direct contacts between 
   
     
     
     
   
     
   




the IBC and the C-terminal domain (CTD) (Fig. 2A), which is contiguous with the pore [12]. 
The IBC and NT fragments can be expressed as soluble proteins in bacteria and recognise 
IP3 and related ligands with the same specificity as native IP3R [11, 13]. Here we use IBC 
and NT fragments of IP3R1 to demonstrate the utility of FP for analyses of ligand binding to 
IP3R [14]. For these analyses we use IP3 labelled at its 2-position with fluorescein 
isothiocyanate (FITC-IP3) because 2-modified analogues of IP3 bind to the IBC and activate 
the IP3R [11]. We initially confirmed the validity of the FP assay by measuring the affinities of 
FITC-IP3, IP3 and adenophostin A (Fig. 2B) to the NT and IBC and the results were 
comparable to those obtained using conventional radioligand binding assays [14]. 
Adenophostin A is a metabolically stable, high-affinity agonist of IP3Rs and residues within 
the IBC are sufficient to confer the high-affinity binding [13]. Typical results obtained using 
the FP assay are shown in figure 2. These include an equilibrium saturation curve with FITC-
IP3 and increasing concentrations of the NT (Fig. 2C), and equilibrium competition curves 
using IP3 or adenophostin A as competing ligands and a fixed concentration of the NT (Fig. 
2D). In a typical equilibrium competition binding assay, a single 96-well plate provides 
sufficient data to determine the KD for 3 different ligands (using 15 concentrations of each 
ligand in duplicates). The non-destructive nature of the assay allows analysis of the effects 
of temperature on ligand binding. The same 96-well plate can be used repeatedly to 
measure the KD of the 3 ligands at 6 different temperatures in less than 3 hours. These 
analyses can then provide estimates of the enthalpy (H) and entropy (S) changes 
associated with ligand binding (Fig. 2E). Re-using the same plate for repeated 
measurements reduces the variability due to plate-to-plate differences and it makes efficient 
use of precious materials. Similar experiments using radioligand binding assays would have 
been impracticable due to the need of expensive radioligands, time (i.e. would have taken 
several days to complete) and the fast off-rates at high temperatures.    
[Fig 2 near here] 
5 
 
Our FP assay, once optimized, provides a rapid (1-3 hours) and relatively inexpensive way 
of measuring ligand binding to IP3R and its fragments in real-time. Since it does not require 
separation of ligand and protein, it can detect even low-affinity interactions. The assay 
avoids use of radioactive materials, it is non-destructive and it can resolve Gibbs free energy 
(ΔG°), enthalpy (ΔH°) and entropy (ΔS°) changes of ligand binding. The protocol is divided 
into 5 steps comprising optimization (3.1), preparation of plates for equilibrium saturation 
(3.2) or competition (3.3) binding assays, anisotropy measurements (3.4) and data analysis 
(3.5). We describe the methods to use with the NT and FITC-IP3. Other fragments and 
fluorescent ligands can be used, but the protocol would need to be modified accordingly.  
 
2. Materials 
1. Ca2+-free cytosol-like medium (Ca2+-free CLM): 140mM KCl, 20mM NaCl, 2mM 
MgCl2, 1mM EGTA and 20mM PIPES, pH 7.0. Use ultrapure water (purified using 
Milli-Q or similar) and analytical grade reagents. The solution can be stored at 4°C for 
several months. 
2. "FITC-IP3" (D-2-O-(2-(3-(5-fluoresceinyl)thioureido)ethyl)-myo-inositol 1,4,5-
trisphosphate). FITC-IP3 was synthesized and purified as described [14]
 (see Note 
1). 
3. Purified N-terminal fragments of IP3R. N-terminal fragments of IP3R1 were expressed 
in E. coli and then purified and quantified (see Note 2) as previously described [1]. 
We used the N-terminal (NT, residues 1-604 of IP3R1) and the IP3-binding core (IBC, 
residues 224-604 of IP3R1), but other fragments or mutant versions could be used. 
4. Half-area, black, flat-bottomed, polystyrene 96-well microplates. 
5. Inositol 1,4,5-trisphosphate hexapotassium salt (IP3) and other competing ligands 
(see Note 3). 
6. Bench-top centrifuge for 96-well plates. 
7. Multi-channel (8-channel) for using with 96-well plates and tips. 
8. Plate-reader suited for FP measurements (eg, PHERAstar, BMG Labtech).  
6 
 
9. Curve-fitting software. 
 
3. Methods 
3.1 Optimization of an FP assay for N-terminal fragments of IP3R (see Note 4).  
3.1.1 Assess whether the fluorescence intensity of the ligand (here FITC-IP3) changes upon 
binding to NT (see Note 5). 
1. Prepare 15 dilutions of NT (with final concentrations ranging between 1-300nM) by 
serially diluting the purified NT sample (“serially diluted NT”). 
2. Mix each concentration of purified protein with FITC-IP3 (final concentration, 0.5nM) 
in Ca2+-free CLM. 
3. Load duplicate 50-l samples of each dilution into individual wells of a 96-well plate. 
4. Centrifuge the plate (300xg, 2min, 20oC).  
5. Incubate for 20min to allow equilibrium to be attained. 
6. Measure the intensity of the fluorescence emitted at 520nm with excitation at 485nm 
using a suitable plate-reader (eg, PHERAstar). Note that no measurements of 
polarized light are required in this step. 
3.1.2 Establish the optimal concentration of FITC-IP3 to be used in the assay. 
1. Prepare serial dilutions of FITC-IP3 (final concentrations, ~0.1nM to ~5nM) in Ca
2+-
free CLM. 
2. Load duplicate 50-l samples of each dilution into a 96-well plate.  
3. Centrifuge the plate (300xg, 2min, 20oC).  
4. Measure fluorescence intensity in the parallel (I) and perpendicular planes (I) and 
thereby anisotropy (A) (see equation 2) using the PHERAstar plate-reader as 
described in “Anisotropy measurements”. 
5. Choose the lowest concentration of FITC-IP3 (to keep it below its equilibrium 




3.1.3 Assess whether the protein interferes with the detection of polarized light (see Note 6). 
1. Mix “serially diluted NT” (final concentrations, 1-300nM) with FITC-IP3 (final 
concentration, 0.5nM) and saturating IP3 (final concentration, 10M) in Ca
2+-free CLM. 
2. Load duplicate 50-l samples into a 96-well plate.  
3. Mix by shaking the plate gently (30rpm, 20oC) using the orbital shaking mode in the 
PHERAstar plate-reader (or an orbital shaker). 
4. Centrifuge (300xg, 2min, 20oC).  
5. Incubate for 20min and then measure I and I (and thereby A) using the PHERAstar 
plate-reader as described in “Anisotropy measurements”. 
   
3.2 Preparation of plates to perform FP equilibrium saturation binding assays  
1. Prepare 15 dilutions of the purified NT (with final concentrations ranging between 1-
300nM) by serially diluting the purified NT sample (“serially diluted NT”). 
2. Load a 96-well plate with duplicate 50-l samples in Ca2+-free CLM of: 
a. Each dilution of “serially diluted NT” and FITC-IP3 (final concentration, 0.5nM) to 
determine AM (the measured A, Fig. 1C) for each NT concentration, and AD*R (the 
anisotropy of bound fluorescent ligand, D*, Fig. 1C) from the well containing the 
highest concentration of NT; 
b. Each dilution of “serially diluted NT” and FITC-IP3 (final concentration, 0.5nM), with 
a saturating concentration of IP3 (final concentration, 10M) to determine AI (A in 
the presence of saturating competing ligand, Fig. 1C) and thus ANS (A due to 
nonspecific binding of D*, Fig. 1C) at each NT concentration; 
c. Each dilution of “serially diluted NT” alone to measure background fluorescence (I 
and I) at each NT concentration. If background fluorescence values are significant, 
they must be subtracted from the equivalent measurements in the presence of 
FITC-IP3 before calculating A; 
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d. FITC-IP3 (final concentration, 0.5nM) to determine AD* (the anisotropy of free D, Fig. 
1C). 
 Each of these conditions (a-d) should be included in every plate.  
3. Mix by shaking plate (30rpm, 15min, 20oC) using the orbital shaking mode in the 
PHERAstar plate-reader (or an orbital shaker).  
4. Wrap plates and samples in foil to minimize exposure to light.  
5. Centrifuge plate (300xg, 2min, 20oC).  
6. Incubate the plate in the dark at the desired temperature (4-37C) for 20min to allow 
equilibrium to be attained (see Note 7). 
7. Using the PHERAstar plate-reader, measure I and I (and thus A).  
  
3.3 Preparation of plates to perform FP equilibrium competition binding assays.  
1. Prepare 8 dilutions of competing ligand (eg IP3) with final concentrations ranging 
between 3nM-150M) by serially diluting the stock (“serially diluted competing 
ligand”) (see Note 8). 
2. Load a 96-well plate with duplicate 50-l samples in Ca2+-free CLM containing: 
a. Each dilution of “serially diluted competing ligand”, FITC-IP3 (final concentration, 
0.5nM) and NT (final concentration, 80nM) to determine AM at each concentration of 
competing ligand, and AI at a saturating concentration of the competing ligand; 
b. FITC-IP3 alone (final concentration, 0.5nM) to measure AD*; 
c. FITC-IP3 (final concentration, 0.5nM) and a saturating concentration of NT (final 
concentration, 300nM), to determine AD*R (under these conditions all FITC-IP3 
should be bound) (see Note 9); 
d. NT (final concentration, 80nM) to measure background I and I. 
3. Mix by shaking plate (30rpm, 15min, 20oC) using the orbital shaking mode in the 
PHERAstar plate-reader (or an orbital shaker). 
4. Wrap plates and samples in foil to minimize exposure to light.  
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5. Centrifuge the plate (300xg, 2min, 20oC).  
6. Incubate the plate in the dark at the desired temperature (4-37C) for 20min to allow 
equilibrium to be attained (see Note 7). 
7. Using the PHERAstar plate-reader, measure I and I (and thus A).  
 
3.4 Anisotropy measurements.  
Here we describe the methods to use a PHERAstar fluorescence polarization plate-reader. 
Similar equipment from other providers is also suitable, but modified procedures will be 
required. 
1. Open the PHERAstar software and select the FP option. Insert the FP 485/520/520 
optic module. Set the following options: 3 cycles of measurement, 300 flashes per 
cycle, 1s positioning delay, and reading direction 11. 
2. Use the well containing only 50l of 0.5nM FITC-IP3 to perform auto-adjustment of 
focal height and gain. The ‘mP Target’ value should be set to 25. The focal height for 
50l of solution in a half-area well should be ~6.3 (see Note 10), 
3. With the above settings take measurements from every well in the plate. The 
samples are excited with light polarized in the horizontal plane at 485nm, and emitted 
light at 520nm is collected simultaneously in both the horizontal (parallel, I) and 
vertical (perpendicular, I) planes. 
4. For repeated measurements of the same plate at different temperatures, both plate-
reader and plate should be re-equilibrated to the desired temperature. After 
equilibration and before performing measurements, the plate should be incubated for 
20min at each temperature to allow reactions to attain equilibrium (see Note 11). 
 
3.5 Data analysis 
Before proceeding with analysis, prepare suitable spreadsheets (eg, Microsoft Excel) to 




1. For each measurement, subtract the background fluorescence I and I caused by the 
presence of protein (here NT) alone. Use these corrected values to calculate the 
measured A (AM, see Fig. 1C) using equation 2.  
2. Using equation 2, similarly calculate AI (A determined in the presence of a saturating 
concentration of a competing ligand) from values of I and I determined for each NT 
concentration in the presence of a saturating concentration of competing ligand (IP3). 
From the calculated AI and AD* (A for free D
*, here FITC-IP3), compute ANS (A due to 
non-specific binding, see Fig. 1C) at each NT concentration using: 
                                          
where FB (the fraction of bound D
*) is calculated using: 
   
      
        
                  
and AD*R denotes A for D
* bound to R. 
3. For each determination of AM and its corresponding ANS, calculate AS (A due to 
specific binding of FITC-IP3) using: 
AS = AM – ANS          (equation 5) 
4. Use the AS value (calculated from equation 5) directly to plot the saturation binding 
curve or to calculate the fraction of D* (fluorescent ligand, here FITC-IP3) bound to R 
(receptor, here NT) using: 
     
     
  
      




where [D*]T denotes the total concentration of D
*. 
5. If [R]T (the total R concentration) is high enough to ensure minimal depletion of the 
free R concentration [R] after binding D* (and thereby [R]T  [R]), plot directly AS 
against [R]T to obtain a binding curve. If [R]T is too low to avoid a significant decrease 
in [R] as it binds to D*, [R] should be calculated for each condition before plotting the 
binding curve using: 
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(equation 7) 
where KD is the equilibrium dissociation constant and [D
*] and [D*]T are the free and total 
concentrations of D*, respectively. In either case, use any suitable curve-fitting program to fit 
the results to a Hill equation: 
   
 




    
   
  
 
     (equation 8) 
where α denotes the fraction of D* specifically bound, and h is the Hill coefficient. From this, 
determine the   
   , that is KD of the interaction between D
* and R. 
6. Once the   
    is established, the KD of any competing ligand (  
      can be computed 
(see Note 12). For equilibrium competition binding measurements, calculate AM and 
then AS from each measurement and from these AS values compute the total 
concentration (I50) of the inhibitor (I) that displaces 50% of D
* specifically bound. From 
the I50 value and the known [R]T, calculate the free concentration of I (IC50) that 
displaces 50% of specifically bound D*. At the I50, 50% of all R are occupied by I, 
hence:   
IC50 = I50 – [R]T/2   (equation 9) 
 
7. From AS value measured at the I50 (  
     ), calculate the [D*R] at the I50 ([D





8. The KD of I for the binding site (  
    ) is then calculated using:  
 
  
      
                 
    
                
              
      
        




           
    
  
         






9. From experiments performed at different temperatures, the KD can be calculated from 
saturation or competition experiments at each chosen temperature. The following 
equations define the relationships between KD, ΔG
o (standard Gibbs free energy 
change), ΔSo (standard entropy change) and ∆Ho (standard enthalpy change): 
ΔG° = RTlnKD (equation 12) 
ΔG° = ΔH° – ΔS° (equation 13) 
where R is the universal gas constant and T the absolute temperature. If ∆Ho is temperature-
independent (ie, the change in heat capacity, ∆C = 0), a van’t Hoff plot (lnKD versus 1/T) can 
be used to obtain ∆H/R from the slope. In cases where ΔC ≠ 0, the following equation 
should be used [15]: 
   
      
      
              
      
    
 
  
    (equation 14) 
where T is the actual absolute temperature, and To is the reference absolute temperature 
(here 296 K).  
10. Determine ΔHo, ΔSo and ΔCo by least-squares curve-fitting of ΔGo versus T. 
 
4. Notes 
1. This protocol is described for FITC-IP3, but other fluorescent ligands can be used. If 
using other fluorophores, ensure the excitation and emission wavelengths used are 
optimal for the chosen fluorophore and that binding to the protein does not affect the 
fluorescent properties of the ligand (see also Note 5).  
2. Accurate determination of the concentration of functional ligand-binding sites in the 
purified protein is crucial for all FP experiments. We used conventional radioligand 
binding assays with 3H-IP3 to determine the density of binding sites in the purified 
protein sample [1]. In all analyses, the concentration of purified protein refers to the 
concentration of functional binding sites. 
3. The specific needs of each experiment will determine the need for other ligands (eg, 
adenophostin A, synthetic analogues of IP3R, etc [11]).  
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4. This protocol is described for the NT. For the IBC, use 10-fold lower concentrations 
of functional binding sites (because its affinity for IP3 is ~10-fold higher than the NT). 
If using other fragments or mutant fragments, determine their KD for IP3 by other 
methods and adjust the concentration of functional binding sites accordingly.  
5. For a fluorescent ligand to be suitable for FP analyses, its rate of depolarization, but 
not its fluorescence intensity, should change when binding to the protein. If the 
fluorescence intensity of the ligand changes upon binding the protein, try another 
fluorescent ligand. This might be achieved by either conjugating the fluorophore to a 
different position or using a different fluorophore.   
6. For all FP measurements, it is crucial to determine whether the protein itself 
interferes with the detection of polarized light. Here measurements are performed in 
the presence of a large excess of unlabelled ligand in order to prevent binding of 
FITC-IP3 to NT. If attenuation of the emitted light is the same in both planes (I and 
I), it will not affect measurements of A. Otherwise a correction will be required. 
7. The time required for reactions to attain equilibrium will depend on the protein and 
ligand, their concentrations and the temperature. The timing must be optimised for 
each set of conditions. If equilibrium has not been attained before performing 
measurements for a given set of conditions, optimise the timing by measuring the 
same plate at regular intervals (eg, every 5min) to follow the increase in A overtime. 
Determine the time at which A reaches a plateau, indicating that equilibrium has 
been attained. 
8. The concentrations of the competing ligand used should cover a range of at least 
100-fold either side of its KD for the protein used. 
9. The concentration of purified protein used should be optimized to both avoid wasting 
valuable material and to maximize the dynamic range. Choose the lowest possible 
protein concentration to ensure that most fluorescent ligand (here FITC-IP3) is bound 
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to the protein before addition of competing ligand. We found that protein 
concentrations that gave A greater than 50% of AD*R (Fig. 1C) worked well. 
10. Optimally adjust the gain and focal height to achieve maximal sensitivity. 
11. High temperatures might affect the stability of the ligand or the protein (e.g., by 
causing protein damage or ligand degradation). Verify that the effects of increasing 
temperature are reversible by measuring the plate at the lowest chosen temperature, 
then equilibrating the plate at the highest temperature, and repeating the 
measurement after returning the plate to the lowest temperature. The PHERAstar 
plate reader is equipped with a temperature-control system. If using a plate reader 
without temperature control, the plate reader should be housed in a temperature-
controlled cabinet. 
12. In conventional radioligand binding experiments, the Cheng and Prusoff equation can 
be used to calculate the KD from the concentration of drug that displaces 50% of 
specifically bound radioligand (IC50) [16]. In FP experiments, the relationships 
between total and free concentrations are more complicated, so the   
     cannot be 
calculated using the Cheng-Prusoff equation [17]. 
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Figure 1. Use of fluorescence polarization to measure ligand binding. (A) When an immobile 
fluorophore is excited with plane-polarized light, 60% of the emitted light remains polarized 
with respect to the excitation source (i.e. parallel). If the molecule rotates during its 
fluorescence lifetime, then less than 60% of the emitted light will remain polarized in the 
parallel plane and more light will be collected in each of the perpendicular planes [3]. FP 
measures the emission by a fluorophore in two planes (horizontal and vertical) after 
excitation with polarized light in one of these planes. As described in equation 2, anisotropy 
(A) is defined by the relationships between the intensities of the light detected in the parallel 
(I) and perpendicular (I) planes with respect to the excitation light. For an immobile 
fluorescent molecule: A = (60 – 20)/(60 + 40) = 0.4. [3]. If the molecule rotates and becomes 




where Ai is the anisotropy of each molecule and fi denotes its fractional fluorescence 
intensity. As the fraction of reoriented molecules increases, A decreases linearly from a 0.4 
(its maximum value) to 0. (B) A small fluorescent ligand (D*) free in solution rotates rapidly 
due to its small molecular volume. If D*is excited with plane-polarized light, it will emit 
depolarized light and thus will have a low A (top). If D* binds to a large protein (R), its 
molecular volume will increase and it will therefore rotate less (i.e. the speed of rotation is 
inversely related to molecular volume [3]). Thus, more of the emitted light will remain 
polarized with respect to the excitation light, causing A to increase (bottom). (C) The 
maximal dynamic range of an FP assay is given by the anisotropy (A) of the free D* (AD*) and 
bound D* (ADR*). AM, the measured A for each experimental condition, includes A from free 
D*, and D* specifically bound to R and non-specifically bound to other components. AI (for 
each experimental condition), is the A measured in the presence of a saturating 
concentration of a competing ligand (I) which causes displacement of all D* specifically 
bound. ANS (defined as A due to non-specific binding) is calculated from AI using equations 
         
 




2-4 and AS (A due to specific binding) using equation 5. Reproduced, with modifications from 
[1].  
 
Figure 2. FP measurements of equilibrium ligand binding to N-terminal fragments of IP3R 
(A) Cartoon of a single subunit of IP3R1 showing its key domains: the NT (residues 1-604) 
which comprises the IBC and SD, 6 transmembrane domains (black lines) and the C-
terminal domain (CTD). (B) Chemical structures of IP3, FITC-IP3 and adenophostin A. (C) 
Anisotropy measurements from a typical FP saturation binding assay using FITC-IP3 (0.5 
nM) and the indicated concentrations of purified NT performed in Ca2+-free CLM at 4. (D) 
Typical results from a FP competition binding assay using FITC-IP3 (0.5 nM), NT (80nM) and 
the indicated concentrations of competing ligands in Ca2+-free CLM at 4. (E) Typical van’t 
Hoff plots for IP3 and adenophostin A binding to the NT. Results (C-E) are means ± S.E.M., n 
= 3. Original data reproduced from [14] with permission from The American Society for 
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